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Abstract: Acidosis is a biochemical hallmark of the tumor microenvironment. Here, we 
report that acute acidosis decreases c-Myc oncogene expression in U937 human lymphoma 
cells. The level of c-Myc transcripts, but not mRNA or protein stability, contributes to  
c-Myc protein reduction under acidosis. The pH-sensing receptor TDAG8 (GPR65) is 
involved in acidosis-induced c-Myc downregulation. TDAG8 is expressed in U937 
lymphoma cells, and the overexpression or knockdown of TDAG8 further decreases or 
partially rescues c-Myc expression, respectively. Acidic pH alone is insufficient to reduce 
c-Myc expression, as it does not decrease c-Myc in H1299 lung cancer cells expressing 
very low levels of pH-sensing G protein-coupled receptors (GPCRs). Instead, c-Myc is 
slightly increased by acidosis in H1299 cells, but this increase is completely inhibited by 
ectopic overexpression of TDAG8. Interestingly, TDAG8 expression is decreased by more 
than 50% in human lymphoma samples in comparison to non-tumorous lymph nodes and 
spleens, suggesting a potential tumor suppressor function of TDAG8 in lymphoma. 
Collectively, our results identify a novel mechanism of c-Myc regulation by acidosis in the 
OPEN ACCESS
Int. J. Mol. Sci. 2013, 14 20237 
 
 
tumor microenvironment and indicate that modulation of TDAG8 and related pH-sensing 
receptor pathways may be exploited as a new approach to inhibit Myc expression.  
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1. Introduction 
The c-Myc oncogene is a member of the Myc family, which also includes L-Myc, N-Myc, S-Myc 
and B-Myc [1–3]. Myc plays critical roles in many aspects of cellular processes, such as cell growth, 
metabolism, apoptosis and cell fate determination [4,5]. c-Myc promotes cell cycle progression  
from the G0/G1 into the S phase by activating cell cycle-promoting genes and inhibiting cell  
cycle suppressors [6–8]. Furthermore, c-Myc regulates cell metabolism, synthesis of RNA and protein, 
as well as genomic instability and metastasis [9–13]. c-Myc, synergizing with other oncogenes, such as 
BCL-2, RAS and RAF, drives cell transformation [14]. Myc deregulation is associated with 
tumorigenesis and poor disease prognosis. Aberrant overexpression of Myc through gene amplification 
and translocation and transcriptional and translational regulations has been observed in many types  
of cancer [1].  
The expression of c-Myc is tightly regulated at multiple levels [1,5,15–17]. At the transcriptional 
level, the c-Myc promoter is potentially bound by several transcriptional factors, such as TCF4,  
LEF-1, β-catenin, γ-Catenin, E2F-1, p53 and NFκB. Many signaling pathways, including the  
PI3K-Akt-mTOR, Ras-Raf-MEK-ERK/MAPK, TGF-β, NFκB and Wnt pathways, regulate c-Myc 
mRNA expression. Small GTPase pathways, such as Ras and Rac, are also involved in c-Myc 
transcriptional regulation. Moreover, c-Myc expression is regulated at the posttranscriptional level, 
including mRNA stability and translation and protein stability and modification.  
Tumor microenvironment is characterized by acidosis, which is due to the production of hydrogen 
ions from lactic acid by glycolysis (“Warburg effect”) and from other sources, such as carbonic acid 
and ATP hydrolysis [18–21]. Acidosis can be cytotoxic, retard cancer cell proliferation, induce 
dormancy and lead to apoptosis [22–26]. Microarray and biochemical studies demonstrate that acidosis 
inhibits glycolysis and Akt activities in breast cancer cells, and the gene signature induced by acute 
acidosis is correlated with favorable prognosis in breast cancer patients [27]. However, chronic 
acidosis is proposed as a selection pressure for cancer cell somatic evolution in a Darwinian  
manner [28–30]. Autophagy is a protective mechanism for tumor cells to survive in chronic  
acidosis [31,32]. It is also shown that acidosis facilitates cancer cell invasion by degrading 
extracellular matrix [33,34]. Thus, the roles of acidosis in tumor biology are very complex, depending 
on acute versus chronic effects and the biological context. 
A family of G protein-coupled receptors (GPCRs), including GPR4, TDAG8 (GPR65), OGR1 
(GPR68) and G2A (GPR132), has been identified as proton sensors [35–42]. TDAG8 is highly 
expressed in lymphoid tissues and lymphoma and leukemia cell lines [43–47]. Both tumor-promoting 
and tumor-suppressing activities of TDAG8 have been reported. Ectopic overexpression of TDAG8 
increases the tumor growth of lung carcinoma cells [48]. In WEHI7.2 and CEM-C7 T-cell lymphoma 
cell lines, TDAG8 is activated by acidosis to promote the evasion of apoptosis under glutamine  
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starvation [49]. On the other hand, TDAG8 has also been reported as a tumor suppressor, which 
promotes glucocorticoid-induced apoptosis in murine lymphoma cells and thymocytes [45,47]. 
Moreover, TDAG8 (T-cell death-associated gene 8) was originally identified as a gene substantially  
upregulated during T-cell apoptosis [43]. TDAG8 as a pH sensor is highly relevant in lymphomas, 
because these tumors have abundant proton production and high TDAG8 expression. However, the 
biological roles of TDAG8 in lymphoma remain ill-defined.  
Here, we demonstrate that acidosis and TDAG8 suppresses the expression of the c-Myc oncogene 
in lymphoma cells. Our results also show that TDAG8 expression is significantly decreased in human 
lymphoma samples in comparison to normal lymphoid tissues, suggesting a potential tumor suppressor 
function of TDAG8 in lymphoma.  
2. Results 
2.1. c-Myc Protein Is Downregulated by Acidic pH Treatment in U937 Lymphoma Cells 
The expression of the critical cell regulator c-Myc was examined in U937 lymphoma cells treated 
with the physiological pH 7.4 and the acidic pH 6.4. Western blotting with a c-Myc-specific antibody 
revealed that the c-Myc protein level was reduced by approximately 50% under the 3-h and 6-h 
treatment of pH 6.4 when compared to the pH 7.4 treatment (Figure 1A,B). Similar c-Myc 
downregulation by acidic pH was also observed in Ramos lymphoma cells and Jurkat T-cell leukemia 
cells (Figure 1C,D).  
Figure 1. c-Myc protein is downregulated by acidosis in lymphoma and leukemia cell 
lines. (A) U937 lymphoma cells treated with pH 7.4 or pH 6.4 for three and 6 h were 
subject to Western blot assay using anti-c-Myc antibody. β-Actin was used as a loading 
control; (B) Quantification of U937 cell Western blot results. The expression of c-Myc in 
the 3-h pH 7.4 treatment was set as one. The data presented were derived from nine 
biological replicates. Error bars indicate ±SEM. * p < 0.05; *** p < 0.001; (C) Western 
blot analysis of Ramos lymphoma cells treated with pH 7.4 or pH 6.4 for three and 6 h;  
(D) Western blot analysis of Jurkat T-cell leukemia cells treated with pH 7.4 or pH 6.4 for 
three and 6 h.  
 
2.2. Downregulation of c-Myc Protein by Acidosis Is Due to Reduced c-Myc Transcriptional Level,  
but not mRNA or Protein Stability, in U937 Lymphoma Cells 
In order to elucidate the cause of c-Myc downregulation by acidic pH, the mRNA transcript  
level and the mRNA and protein stability of c-Myc were examined. Real-time RT-PCR (reverse  
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transcriptase-polymerase chain reaction) showed that c-Myc mRNA was reduced by 50% under 3-h 
and 6-h pH 6.4 treatment (Figure 2A), which was close to the level of c-Myc protein reduction  
(Figure 1). The stability of c-Myc mRNA was determined by treating U937 cells with the transcription 
inhibitor actinomycin D, and then, the rate of c-Myc mRNA decay was measured by  
real-time RT-PCR. The half-life of c-Myc mRNA was approximately 1 h in U937 cells, and there was 
no significant difference in c-Myc mRNA stability between the treatment with pH 7.4 and pH 6.4, 
except a slight reduction of c-Myc/GAPDH, but not c-Myc/18S rRNA by pH 6.4 at 15 min  
(Figure 2B). To examine c-Myc protein stability, U937 cells were treated with the translation inhibitor 
cycloheximide and the c-Myc protein level was determined by Western blotting. The results showed 
that the half-life of c-Myc protein was approximately 3 h in U937 cells, and there was no significant 
difference in c-Myc protein stability between the pH 7.4 and the pH 6.4 treatments (Figure 2C). 
Altogether, our data suggest that mRNA expression level, but not mRNA or protein stability accounts 
for c-Myc downregulation under acidosis. 
Figure 2. c-Myc transcriptional level, but not mRNA or protein stability, is downregulated 
by acidosis in U937 cells. (A) c-Myc mRNA is decreased by pH 6.4 treatment. U937 cells 
treated with pH 7.4 or pH 6.4 for three and 6 h were subject to total RNA isolation and  
real-time RT-PCR using c-Myc-specific primer probes. GAPDH (glyceraldehyde  
3-phosphate dehydrogenase) was used as an internal control for normalization; (B) c-Myc 
mRNA stability is not altered by acidosis. U937 cells grown in HEM (7.5 mM HEPES,  
7.5 mM EPPS and 7.5 mM MES)-buffered medium with 5 μg/mL actinomycin D at pH 7.4 
or pH 6.4 for the indicated times were subject to total RNA extraction and real-time  
RT-PCR using c-Myc-specific primer probes. GAPDH (left) and 18S rRNA (right) were 
used as internal controls. The expression of c-Myc under 15 min of pH 7.4 plus 
actinomycin D treatment was set as one; (C) c-Myc protein stability is not altered by 
acidosis. Left panel: U937 cells grown in HEM-buffered medium with 50 μg/mL 
cycloheximide (CHX) at pH 7.4 or pH 6.4 for the indicated times were subject to total 
protein extraction and Western blot using anti-c-Myc antibody. β-Actin was used as a 
loading control. Right panel: quantification of Western blot results. The expression of  
c-Myc under the 15-min treatment with pH 7.4 and CHX was set as one. The data 
presented were derived from at least three biological replicates. Error bars indicate ±SEM. 
* p < 0.05; *** p < 0.001; ns, not significant (p > 0.05). 
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2.3. c-Myc Protein Is Decreased by TDAG8 Overexpression and Increased by TDAG8 Knockdown in 
U937 Lymphoma Cells 
We next investigated the molecular mechanisms by which U937 lymphoma cells sense the acidic 
microenvironment and cause c-Myc downregulation. Previous studies demonstrate that TDAG8 and 
G2A are predominantly expressed in lymphoid tissues and leukocytes [43–47,50]. Our RT-PCR results 
also showed that among the proton-sensing GPCRs, TDAG8 and G2A have the highest expression 
levels and OGR1 has a relatively low expression, whereas GPR4 is barely detectable in U937 
lymphoma cells (Figure 3A). Because it has been reported that TDAG8 is the major proton sensor in 
lymphocytes and the proton-sensing function of G2A is controversial [39], we focused on TDAG8 to 
test whether it is involved in acidosis-induced c-Myc downregulation. 
U937 cells were stably transduced with the MSCV (Murine Stem Cell Virus)-IRES (Internal 
Ribosome Entry Site)-GFP (Green Fluorescent Protein) vector (U937/vector cells) or the  
MSCV-TDAG8-IRES-GFP construct (U937/TDAG8 cells). Real-time RT-PCR confirmed the 
overexpression of TDAG8 in U937/TDAG8 cells with a 25-fold increase in mRNA level (Figure 3B). 
We were not able to examine TDAG8 protein level, because several commercially available TDAG8 
antibodies we tested did not work (data not shown). When U937/vector and U937/TDAG8 cells were 
treated with pH 7.4 and pH 6.4 for 3 h, c-Myc protein was reduced by approximately 50% at pH 6.4 in 
U937/vector cells (Figure 3C,D), similar to what was observed in parental U937 cells (Figure 1). 
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TDAG8 overexpression further reduced c-Myc expression in the pH 7.4 treatment (24% of decrease) 
and the pH 6.4 treatment (75% of decrease) when compared to U937/vector cells at pH 7.4  
(Figure 3C,D). The partial pH-sensing activity of TDAG8 at pH 7.4 is consistent with previous  
reports [35,41]. Furthermore, TDAG8 was knocked down by shRNA in U937 cells. The mRNA of 
TDAG8 was reduced by 50% in U937/TDAG8-shRNA cells in comparison to U937/scramble-shRNA 
cells (Figure 3E). c-Myc protein expression was increased in U937/TDAG8-shRNA cells when 
compared to U937/scramble-shRNA cells (Figure 3F,G), which demonstrated that TDAG8 knockdown 
partially rescued c-Myc expression. This partial rescue may be attributed to these reasons: the 
knockdown efficiency of TDAG8 is only 50%, and the related family members G2A and OGR1 
expressed in U937 cells may cause genetic redundancy. Nonetheless, the results suggest that TDAG8 
negatively regulates c-Myc expression in U937 lymphoma cells. 
Figure 3. The expression of c-Myc protein is decreased by TDAG8 overexpression and 
increased by TDAG8 knockdown in U937 cells. (A) TDAG8 is highly expressed in U937 
cells. Total RNA was isolated from U937 cells and subject to RT-PCR using gene-specific 
primers of GPR4, G2A, TDAG8 and OGR1. β-Actin was used as a positive control;  
(B) Real-time RT-PCR detecting TDAG8 expression in U937/vector and U937/TDAG8 
cells; (C) U937/vector and U937/TDAG8 cells were treated with HEM-buffered RPMI 
(Roswell Park Memorial Institute) medium at pH7.4 or pH 6.4 for 3 h and then subject to 
Western blot using anti-c-Myc antibody. β-Actin was used as a loading control;  
(D) Quantification of Western blot results. The expression of c-Myc in U937/vector cells 
under the three-hour pH 7.4 treatment was set as one; (E) Real-time RT-PCR of TDAG8 in 
U937/scramble-shRNA and U937/TDAG8-shRNA cells; (F) U937/scramble-shRNA and 
U937/TDAG8-shRNA cells were treated with HEM-buffered RPMI medium at pH7.4 or 
pH 6.4 for 3 h and, then, subject to Western blot using anti-c-Myc antibody. β-Actin was 
used as a loading control; (G) Quantification of Western blot results. The expression of  
c-Myc in U937/scramble-shRNA cells under the pH 7.4 treatment was set as one. The 
quantification of Western blot data was derived from at least five biological replicates. 
Error bars indicate ±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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2.4. TDAG8 Downregulates c-Myc Protein in a pH-Dependent Manner 
We further examined the pH-dependence of c-Myc regulation more thoroughly by assessing the 
effects of a wide range of pH, including pH 8.4 (4 nM H+), pH 7.9 (12.6 nM H+), pH 7.4 (40 nM H+), 
pH 6.9 (126 nM H+) and pH 6.4 (400 nM H+). A left shift of the pH response curve was clearly 
observed in U937/TDAG8 cells in comparison to U937/vector cells (Figure 4), suggesting that 
TDAG8 overexpression makes U937 cells more sensitive to the increase of acidity and, also, further 
reduces c-Myc expression. At pH 8.4 in which TDAG8 has minimal activity, the expression of c-Myc 
was not significantly different in U937/vector and U937/TDAG8 cells (Figure 4A,B). These results 
suggest that TDAG8, responsive to the increase of acidity, downregulates c-Myc expression in U937 
lymphoma cells.  
Figure 4. TDAG8 induced c-Myc protein downregulation is pH dependent. (A) Cells 
treated with HEM-buffered RPMI medium at varying pH for 3 h were subject to Western 
blot assay using anti-c-Myc antibody. β-Actin was used as a loading control;  
(B) Quantification of Western blot results. The expression of c-Myc in U937/vector cells 
under the 3-h pH 7.4 treatment was set as one. Error bars indicate ±SEM. * p < 0.05;  
** p < 0.01; *** p < 0.001; ns, not significant (p > 0.05), comparing U937/TDAG8 cells to 
U937/vector cells at each pH, or comparing pH 6.4 to pH 7.4 in U937/vector cells.  
## p < 0.01, comparing pH 6.4 to pH 7.4 in U937/TDAG8 cells.  
 
Int. J. Mol. Sci. 2013, 14 20243 
 
 
Figure 4. Cont. 
 
2.5. The Protein Level of c-Myc Is Moderately Increased by Acidosis in H1299 Lung Cancer Cells,  
but This Increase Is Completely Inhibited by Ectopic TDAG8 Overexpression 
To further elucidate the connection between TDAG8 and acidosis-induced c-Myc downregulation, 
we identified a human lung cancer cell line, H1299, in which c-Myc expression was not decreased by 
acidic pH (Figure 5A). Western blotting revealed two isoforms of c-Myc protein around 59 and  
62 kDa in H1299 cells (Figure 5A). The treatment with pH 6.4, in comparison to pH 7.4, did not result 
in any reduction of c-Myc protein. Instead, c-Myc protein, particularly the big isoform, was 
moderately increased by acidosis (Figure 5A). In addition to H1299 cells, we also found that acidic pH 
did not affect c-Myc protein level in A375 human melanoma cells (data not shown). RT-PCR revealed 
that the expression of the proton-sensing GPCRs, TDAG8 in particular, was very low in H1299 lung 
cancer cells (Figure 5B). To test whether ectopic overexpression of TDAG8 can inhibit c-Myc 
expression, H1299 cells were stably transduced with MSCV-TDAG8-IRES-GFP (H1299/TDAG8 
cells) or MSCV-IRES-GFP (H1299/vector cells). The overexpression of TDAG8 in H1299/TDAG8 
cells was confirmed by RT-PCR (Figure 5B). As observed in parental H1299 cells (Figure 5A), 
treatment with pH 6.4 slightly increased the expression of c-Myc protein, especially the big isoform, in 
H1299/vector cells, whereas ectopic overexpression of TDAG8 completely suppressed the increase of 
c-Myc by pH 6.4 in H1299/TDAG8 cells (Figure 5C–F).  
Collectively, these results demonstrate that acidosis has differential effects on c-Myc expression in 
different cell types. In U937 lymphoma cells with a high level of TDAG8 and related pH-sensing 
GPCRs, acidosis clearly decreases c-Myc expression (Figures 1–4). In H1299 lung cancer cells with a 
low level of pH-sensing GPCRs, acidosis alone is insufficient to reduce c-Myc expression and, instead, 
slightly increases c-Myc through currently unknown mechanisms (Figure 5). However, ectopic 
TDAG8 overexpression can suppress c-Myc expression in H1299 cells at acidic pH (Figure 5).  
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Figure 5. Ectopic overexpression of TDAG8 inhibits the upregulation of c-Myc protein by 
acidosis in H1299 cells. (A) c-Myc protein is moderately increased by acidosis in H1299 
cells. Cells treated with HEM-buffered RPMI medium at pH 7.4 or pH 6.4 for three and 6 h 
were subject to Western blot assay using anti-c-Myc antibody. β-Actin was used as a 
loading control; (B) Low expression of proton-sensing GPCRs in H1299 cells. Total RNAs 
were isolated from H1299 parental, H1299/vector and H1299/hTDAG8 cells and subject to 
RT-PCR using gene-specific primers of GPR4, G2A, TDAG8 and OGR1. β-Actin was 
used as a positive control; (C) c-Myc protein is reduced by ectopic overexpression of 
TDAG8. Cells were treated with HEM-buffered RPMI medium at pH 7.4 or pH 6.4 for 3 h 
and, then, subject to Western blot assay using anti-c-Myc antibody. β-Actin was used as a 
loading control; (D–F) Quantification of Western blot results from (C). The expression of 
the total (D), big isoform (E) and small isoform (F) of c-Myc were quantified based on  
six Western blot repeats. The expression of c-Myc under the 3-h pH 7.4 treatment was set 
as one. Error bars indicate ±SEM. * p < 0.05; ** p < 0.01; ns, not significant (p > 0.05). 
 
2.6. Expression of TDAG8 Transcripts Is Significantly Reduced in Human Lymphomas 
To correlate the biochemical function of TDAG8 with tumor biology, we compared the expression 
of TDAG8 transcripts between lymphomas and lymphoid tissues. Real-time RT-PCR was performed 
on lymphoma tissue cDNA arrays containing 84 cDNA samples from lymphoma patients and  
12 cDNA samples from non-tumorous lymph nodes and spleens (see Table S1 for detailed 
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information). The results demonstrated that TDAG8 mRNA expression was decreased by 56% in 
lymphoma samples in comparison to lymph nodes and spleens (p < 0.001) (Figure 6A). To further 
analyze lymphoma subtypes, the TDAG8 mRNA level was decreased by 60%–70% in follicular 
lymphoma, diffuse large B-cell lymphoma and small lymphocytic lymphoma samples when compared 
to normal lymphoid tissues (p < 0.05) (Figure 6B). The expression of TDAG8 mRNA was also 
decreased in other types of lymphomas, such as extranodal marginal zone B-cell lymphoma, 
Hodgkin’s lymphoma, mantle cell lymphoma, splenic marginal zone B-cell lymphoma, nodal marginal 
zone B-cell lymphoma and peripheral T-cell lymphoma, but the results were not statistically 
significant, likely due to the small sample size (Figure 6B). Furthermore, bioinformatic analysis of the 
Oncomine microarray database revealed that the expression of TDAG8 (GPR65) was significantly 
lower (2.021 fold decrease, p < 0.001) in follicular lymphoma when compared to normal lymphocytes 
(Figure 6C), concordant with the real-time RT-PCR results of lymphoma samples (Figure 6A,B).  
Figure 6. TDAG8 expression is lower in lymphomas than that in normal lymphoid tissues. 
(A,B) Human lymphoma tissue cDNA arrays (OriGene Technologies) were subject to  
real-time RT-PCR using TDAG8 specific primer probes. β-actin was used as an internal 
control for normalization. TDAG8 expression was compared between non-tumorous 
lymphoid tissues (lymph nodes and spleens) and all tested lymphoma tissues (A) or 
different subtypes of lymphoma tissues (B). The expression of TDAG8 in lymph nodes and 
spleens was set as one. Each dot represents an individual sample. Error bars indicate 
±SEM. * p < 0.05; *** p < 0.001; ns, not significant (p > 0.05); (C) Analyses of the 
Oncomine cancer microarray database revealed that TDAG8 expression was reduced by 
two-fold in follicular lymphoma in comparison to normal lymphocytes (p < 0.001).  
x-axis: 1, B-lymphocyte; 2, centroblast; 3, memory B-lymphocyte; 4, naive pregerminal 
center B-lymphocyte; 5, small cleaved follicle center cell; 6, follicular lymphoma.  
y-axis: log2 median-centered intensity. 
 
2.7. The Level of TDAG8 mRNA Is Downregulated by Acidosis in U937 Lymphoma Cells 
Since the tumor microenvironment is characteristically acidic, we investigated whether acidosis 
might affect TDAG8 expression in U937 lymphoma cells. The real-time RT-PCR results showed that 
TDAG8 mRNA was reduced by more than 50% under the three-hour pH 6.4 treatment compared to the  
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pH 7.4 treatment (Figure 7). When the treatment was extended to 6 h, the reduction of TDAG8 mRNA 
by acidic pH was about 70%, whereas the TDAG8 level was moderately increased in the pH 7.4 
treatment group (Figure 7). These results suggest that acidosis can downregulate the expression of the 
TDAG8 pH-sensing receptor, and this may represent a potential mechanism by which TDAG8 mRNA 
is decreased in lymphomas in comparison to non-tumorous lymphoid tissues, due to acidosis in the 
tumor microenvironment (Figure 6).  
Figure 7. TDAG8 mRNA is decreased by acidosis in U937 cells. U937 cells treated with 
pH 7.4 or pH 6.4 for three and 6 h were subject to total RNA isolation and real-time  
RT-PCR using TDAG8-specific primer probes. β-actin was used as an internal control for 
normalization. TDAG8 expression under the 3-h pH 7.4 treatment was set as one. The data 
were derived from three biological replicates. Error bars indicate ±SEM. *** p < 0.001. 
 
3. Discussion 
Acidosis, a hallmark of the tumor microenvironment, results from excessive proton production and 
accumulation in a tumor. Initially observed by Otto Warburg decades ago, cancer cells preferentially 
utilize glycolysis, instead of oxidative phosphorylation, to generate ATP and other molecules, even in 
the presence of oxygen [20]. Furthermore, the tumor microenvironment is often hypoxic, due to 
abnormal tumor blood vessels and defective blood perfusion [30,51]. Consequently, glucose  
uptake is increased in cancer cells as an adaptation mechanism, and a large amount of lactic acid is 
produced through glycolysis. The Warburg effect is particularly prominent in lymphoma  
patients as demonstrated by clinical observations that most lymphomas have high activity in  
18F-fludeoxyglucose-positron emission tomography (FDG-PET) [52,53]. Some lymphoma patients 
even develop systemic acidosis, because of the large tumor burden and excessive lactic acid 
production, which is associated with a high mortality rate and poor prognosis [54,55]. Thus, it is 
important to understand how acidosis regulates the cellular and molecular changes of cancer cells.  
In this study, we demonstrate that acute acidosis treatment decreases the expression of the c-Myc 
oncogene in U937 lymphoma cells (Figures 1–4). It has been reported that acute acidosis can cause 
cell apoptosis and necrosis, inhibit cell proliferation and delay carcinogenesis [22–24,26,56]. Episodic, 
transient acidosis is proposed to be a possible mechanism for cancer prevention related to increased 
physical activity [24]. On the other hand, acidosis can facilitate chromosomal instability, gene 
mutation, extracellular matrix degradation and tumor invasion [28–30,33,34,57]. Whereas acute 
acidosis suppresses cell proliferation, chronic exposure to acidosis selects for resistant cancer cells in 
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which autophagy is increased to promote cell survival [31,32]. Because c-Myc is a key regulator of the 
cell cycle, it will be of interest to examine whether c-Myc downregulation by acute acidosis is essential 
for inhibiting cell proliferation and how chronic acidosis may affect c-Myc expression in cancer cells.  
The expression of c-Myc is tightly regulated by transcription, mRNA stability, translation and 
protein modification and stability [5,16]. Our results show that the stability of c-Myc mRNA and 
protein is not affected by acidic pH in U937 lymphoma cells (Figure 2B,C). Instead, acidosis treatment 
decreases the level of c-Myc transcripts by approximately 50%, which is consistent with the level of  
c-Myc protein reduction by acidosis (Figures 1 and 2A). These data indicate that acidosis inhibits the 
transcription of the c-Myc gene. It has been shown that c-Myc gene transcription can be regulated by 
many transcription factors, chromatin modulators and signaling pathways, such as TCF, FBP, SMAD, 
LEF-1, β-catenin, γ-Catenin, E2F, AP1, Sp1-3, p53, NF-κB, BRD4, PI3K-Akt-mTOR and  
Ras-Raf-MEK-ERK/MAPK [17]. The detailed mechanism by which acidosis decreases c-Myc 
transcription remains to be elucidated. 
Our data reveal that the proton-sensing receptor, TDAG8 (GPR65), is involved in acidosis-induced 
c-Myc downregulation in U937 cells. TDAG8 is a member of the proton-sensing GPCR family, which 
is activated by acidic extracellular pH through protonation of histidine residues [36,37]. By genetic 
manipulation of TDAG8 expression, we show that TDAG8, responsive to pH changes, inhibits c-Myc 
expression in U937 lymphoma cells (Figures 3,4). To the best of our knowledge, this is the first study 
to demonstrate that acidosis and the pH-sensing TDAG8 receptor regulate c-Myc expression in cancer 
cells. Interestingly, our quantitative RT-PCR results show that TDAG8 mRNA expression is decreased 
by more than 50% in human lymphoma samples in comparison to normal lymphoid tissues  
(Figure 6A,B). Moreover, analyses of the Oncomine cancer microarray database further demonstrate 
that TDAG8 expression is reduced by two-fold in follicular lymphoma when compared to normal 
human lymphocytes (Figure 6C). Biochemically, our results reveal that acidosis can downregulate 
TDAG8 expression in U937 lymphoma cells (Figure 7). This may explain the reduced mRNA level of 
TDAG8 in human lymphoma samples (Figure 6), because acidosis in the tumor microenvironment 
may lead to the decrease of TDAG8 expression in lymphoma cells. The downregulation of TDAG8 in 
lymphomas is different from a previous report that TDAG8 mRNA is overexpressed in a certain 
percent of kidney, ovarian, colon and breast tumors [58]. However, it should be noted that the 
quantification of TDAG8 mRNA in that previous study was done by real-time RT-PCR using RNA 
samples isolated from whole tumor tissues [58]. Because tumors contain many other types of cells, 
such as infiltrated immune cells, vascular cells and fibroblasts in addition to cancer cells [59], it is 
unclear if the overexpression of TDAG8 mRNA in these epithelial tumors is directly derived from 
cancer cells or from infiltrated immune cells, which are known to highly express TDAG8 [43–47,60]. 
Further studies using in situ detection methods and tissue micro-dissection are certainly needed to 
clarify this issue. Whereas both the pro- and anti-tumorigenic effects of TDAG have been reported in 
different experimental models and cancer cell types [45,48,49,58], the downregulation of TDAG8 in 
lymphomas, together with the TDAG8-induced inhibition of c-Myc oncogene expression, suggests that 
TDAG8 may function as a tumor suppressor in lymphoma.  
Because of the critical roles of Myc in tumor biology approaches inhibiting Myc expression, 
Myc/Max dimerization, Myc/Max DNA binding and Myc target genes have been evaluated for cancer 
therapy [1]. For instance, compound 10058-F4 inhibits c-Myc/Max heterodimerization and causes 
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apoptosis, cell cycle blockade and differentiation in cancer cells [61–63]. Recently, a small-molecule 
bromodomain inhibitor, JQ1, has been identified to suppress c-Myc expression and tumor  
growth through inhibiting the BET bromodomain proteins [64–66]. Despite this progress, no  
Myc-targeting agents have yet been approved for cancer therapy in the clinic. Therefore, it is of great 
interest to develop novel approaches to inhibit Myc for cancer treatment and chemoprevention. 
TDAG8 and related proton-sensing GPCRs may represent potential therapeutic targets. Activation of 
the TDAG8 receptor, such as by its agonists, may be devised to suppress Myc expression in lymphoma 
cells. Importantly, GPCRs have traditionally served as important pharmaceutical targets, accounting 
for 30 to 50 percent of the marketed drugs [67]. A previous study identified a putative TDAG8 agonist 
BTB09089 [68]; however, the authors state that the agonistic activity of this compound is not strong 
enough for in vivo studies. We have tested the BTB09089 compound in lymphoma cells and found that 
its efficiency in activating TDAG8 was very limited, if detectable at all [69]. Further research to 
identify more effective TDAG8 agonists is highly needed.  
In conclusion, our results in this study demonstrate that acidosis and the proton-sensing TDAG8 
receptor inhibit the expression of c-Myc oncogene in lymphoma cells. Moreover, the expression of 
TDAG8 is significantly decreased in human lymphomas in comparison to normal lymphoid tissues and 
lymphocytes, suggesting a potential tumor suppressor role of TDAG8 in lymphoma. These results 
provide novel insights into the molecular mechanisms by which acidosis in the tumor 
microenvironment regulates Myc expression and indicate that the proton-sensing GPCRs, such as 
TDAG8, may be exploited as potential targets for cancer treatment and chemoprevention.  
4. Experimental Section 
4.1. Cell Culture and Treatment 
U937 human lymphoma cells, Ramos human lymphoma cells, Jurkat human T-cell leukemia cells 
and H1299 human lung cancer cells (ATCC) were grown in RPMI 1640 medium (Gibco) containing 
10% fetal bovine serum in a humidified incubator with 5% CO2 at 37 °C. For pH treatment,  
cells were incubated in RPMI medium buffered with 7.5 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 7.5 mM EPPS (3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic 
acid) and 7.5 mM MES (2-(N-morpholino)ethanesulfonic acid) (collectively known as HEM) at 
varying pH for 3 h or 6 h. The pH of HEM-buffered medium was adjusted using HCl or NaOH, as 
previously described [42,70–73]. For the c-Myc protein turnover assay, cells were grown in  
HEM-buffered RPMI medium (pH 7.4 or pH 6.4) with 50 μg/mL cycloheximide (Sigma, Saint Louis, 
MO, USA) for various time periods as indicated and, then, subject to total protein isolation. For the  
c-Myc mRNA decay assay, cells were grown in HEM-buffered RPMI medium (pH 7.4 or pH 6.4) with 
5 μg/mL actinomycin D (Invitrogen, Carlsbad, CA, USA) for various time periods, and then, total 
RNA was isolated. 
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4.2. Western Blotting 
Cells were lysed with ice-cold RIPA (radioimmunoprecipitation assay) buffer, and Western blotting 
was performed as previously described [70–72]. Fifteen micrograms of total protein lysate were mixed 
with LDS (lithium dodecyl sulfate) sample buffer (Invitrogen, Carlsbad, CA, USA) plus 50 mM DTT 
(dithiothreitol) and incubated at 70 °C for 10 min. Protein samples were then separated by SDS 
(sodium dodecyl sulfate)-polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membranes (Invitrogen, Carlsbad, CA, USA). Membranes were blocked in TBST buffer (Tris-buffered 
saline with 0.1% Tween-20) containing 5% BSA (bovine serum albumin) overnight and, then, 
incubated in the same blocking buffer plus anti-c-Myc antibody (D84C12, Cell Signaling, Beverly, 
CA, USA). After being washed with TBST buffer 3 times, membranes were further incubated with 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody (Cell Signaling), 
and protein bands were detected using the Amersham ECL (enhanced chemiluminescence) Select 
Western blotting detection kit (GE Healthcare, Piscataway, NJ, USA). Anti-β-actin primary antibody 
(Cell Signaling) was used for the loading control. Western blot results were quantified using the 
LabWorks software (UVP BioImaging Systems, Upland, CA, USA), and the c-Myc protein level was 
normalized by β-actin loading control. 
4.3. RNA Extraction, RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) and Quantitative 
Real-Time RT-PCR 
Total RNA was isolated using the RNeasy Plus kit (QIAGEN, Valencia, CA, USA). cDNA was 
synthesized using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, USA). Regular RT-PCR 
was performed using GPR4-, G2A-, TDAG8-, OGR1- and β-Actin-specific primers with a program of  
95 °C for 2 min, followed by 35 cycles of 94 °C for 30 s, 58 °C for 30 s and 72 °C for 1 min. The 
primer sequences are: GPR4 5'-GCTCCCAGATCCCATCACAG-3' and  
5'-CACTTTCCCCCGAGTCACAG-3', OGR1 5'-AACAGGGTGGGAAGGGAAGA-3' and  
5'-TGGGCCTCCCTTTGGTAGAT-3', G2A 5'-TCACCAACCACCGGATTTTC-3' and  
5'-GGCTCAGCAGGACTCCTCAA-3', TDAG8 5'-GCATTGCCGTTGATCGGTAT-3' and  
5'-AATGCAGCGAATCAGCAACA-3', and β-Actin 5'-TGACCCAGATCATGTTTGAGA-3' and  
5'-AGGTCCAGACGCAGGATG-3'. Real-time TaqMan PCR was performed using the pre-designed 
TaqMan primer-probes (Invitrogen) for c-Myc (catalog # Hs00153408_m1), TDAG8 (catalog  
# Hs00269247_s1), GAPDH (catalog # Hs99999905_m1) and 18S rRNA (catalog # Hs99999901_s1), 
as previously described [71,72]. Lymphoma tissue cDNA arrays were purchased from OriGene 
Technologies (catalog # LYRT301 and LYRT302) and subject to real-time PCR using specific  
primer-probes for TDAG8 and β-Actin (catalog # Hs99999903_m1). The tissue cDNA arrays 
contained 84 lymphoma samples from patients with various types of lymphoma and 12 control lymph 
nodes and spleens without any tumor (for detailed information, see Table S1 and the vendor’s website: 
http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx).  
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4.4. Plasmid Constructs 
The open reading frame of human TDAG8 (GenBank accession # NM_003608)  
was amplified using the primers designed to contain EcoRI and NotI sites:  
5'-ATAAGAATGAATTCACCATGAACAGCACATGTATTGAAGAA-3' and 5'-ATAAGAATGC 
GGCCGCCTACTCAAGGACCTCTAATTCCAT-3'. The PCR product was digested with EcoRI and 
NotI and cloned into the retroviral expression vector MSCV-IRES-GFP to generate the  
MSCV-TDAG8-IRES-GFP construct. The TDAG8 shRNA construct pLKO.1-TRCN0000011645 
(RHS4533-NM_003608) was purchased from Thermo Scientific, and the control scramble shRNA 
construct was purchased from Addgene (plasmid 1864). 
4.5. Cell Transfection and Transduction 
To generate a stable TDAG8-overexpressing cell line, retrovirus-mediated cell transduction was 
performed as previously described [74]. Briefly, the MSCV-TDAG8-IRES-GFP construct was  
co-transfected with the pCL10A-1 packaging vector into HEK 293T cells to produce retroviral 
particles, which were used for cell transduction to generate U937/TDAG8 and H1299/TDAG8 cells. 
MSCV-IRES-GFP virus was used to generate the control cell lines, U937/vector and H1299/vector 
cells. Lentivirus-based cell transduction was performed to generate the TDAD8 knockdown cell line. 
pLKO.1-TRCN0000011645 was co-transfected with the envelope plasmid pCMV-VSV-G (Addgene, 
plasmid 8454) and packaging plasmid pCMV-dR8.2 dvpr (Addgene, plasmid 8455) into HEK 293T 
cells to produce lentiviral particles, which were then used for cell transduction to generate 
U937/TDAG8-shRNA cells. Cells with stable exogenous gene expression were selected by  
2 μg/mL puromycin. A scramble shRNA lentiviral vector was used to generate the control  
U937/scramble-shRNA cells. 
4.6. Oncomine Database Mining 
Bioinformatic analysis was performed by mining the Oncomine cancer microarray database [75]. 
The gene expression of TDAG8 (GPR65) was compared between normal lymphocytes and follicular 
lymphoma samples (data retrieved July, 2013). 
4.7. Statistical Analysis 
Data were subject to statistical analysis using the GraphPad Prism 5 software (GraphPad Software, 
Inc., La Jolla, CA, USA). Each statistical analysis was derived from at least three independent 
biological replicates. Statistical significance was determined using the unpaired t-test. p < 0.05 is 
considered statistically significant. 
5. Conclusions 
Acidosis and the pH-sensing receptor, TDAG8, inhibit c-Myc oncogene expression in human 
lymphoma cells; TDAG8 transcripts are significantly decreased in human lymphomas in comparison 
to non-tumorous lymphoid tissues.  
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